DTHR - Dthera Sciences

Other OTC - Other OTC Delayed Price. Currency in USD
0.7500
-0.1000 (-11.76%)
At close: 2:18PM EDT
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.7500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7500 - 0.7500
52 Week Range0.4000 - 16.8000
Volume1,200
Avg. Volume880
Market Cap2.001M
Beta (3Y Monthly)8.17
PE Ratio (TTM)N/A
EPS (TTM)-1.4820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
    PR Newswirelast month

    OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May

    NEW YORK , June 5, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...

  • ACCESSWIRE4 months ago

    Dthera Sciences Announces Pursuit of Strategic Transaction

    SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Dthera™ Sciences (DTHR) a leading digital therapeutic company specializing in neurodegenerative diseases, today announced that its Board of Directors has initiated a process to pursue a range of potential strategic transactions to enable the Company to bring its development-stage Alzheimer's product, DTHR-ALZ, to market more rapidly.

  • ACCESSWIRE5 months ago

    Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market

    SAN DIEGO, CA / ACCESSWIRE / February 25, 2019 / Dthera™ Sciences (DTHR), a leading digital therapeutic company specialized in neurodegenerative diseases, is pleased to announce that it has entered into an exclusivity agreement with a company headquartered in Japan for development and commercialization rights to Dthera's lead product, DTHR-ALZ. The exclusivity agreement provides exclusive rights to the Japanese partner to perform feasibility studies in Japan and to negotiate a licensing agreement or other transaction for the Japanese market during the agreed term.

  • ACCESSWIRE5 months ago

    Dthera Sciences SVP to Speak on Keynote Panel about Digital Therapeutics in Biopharma at OCT West Coast Conference

    SAN DIEGO, CA / ACCESSWIRE / February 13, 2019 / DtheraTM Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Martin Culjat, Ph.D., Senior Vice President of Scientific & Regulatory Affairs, will speak on the opening keynote panel at Outsourcing in Clinical Trials West Coast (OCT West Coast). The keynote panel is entitled ''Taking Stock of New Players Entering the Healthcare Space: An Opportunity or Threat for Traditional Biopharma?'' and will focus on the potential impact that non-traditional players such as digital therapeutics can have in the biopharma sector. Dr. Culjat is also giving a separate presentation at the conference, entitled ''Overcoming regulatory challenges in digital therapeutic development.'' This presentation will focus on regulatory considerations in the clinical development of digital therapeutics as well as similarities and differences between clinical trials in digital therapeutics and traditional drug trials.

  • ACCESSWIRE5 months ago

    Dthera Sciences CTO to Present on Digital Therapeutics for NASA at MIT Workshop on Cognitive Performance in Space

    SAN DIEGO, CA / ACCESSWIRE / February 6, 2019 / DtheraTM Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer, will be speaking at a NASA-sponsored workshop on cutting edge and emerging technologies for space health. The Workshop will be hosted by the Translational Research Institute for Space Health (TRISH) and will be held at MIT Media Lab in Cambridge, MA from February 6-7, 2019. The workshop is intended to bring together ideas and evidence that are expected to make major contributions to the understandings of how the environment of a spacecraft can be enriched to maximize human health - specifically behavioral and cognitive health.

  • ACCESSWIRE6 months ago

    Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit

    SAN DIEGO, CA / ACCESSWIRE / January 7, 2019 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer will be speaking at CES, Digital Health Summit, A Brain and Mental Health Crisis Intervention. CES 2019, is January 8-11, 2019 in Las Vegas. Mr. Keene will be discussing the future of digital therapeutics and specifically treatments for those suffering from Alzheimer's and other dementias.

  • ACCESSWIRE7 months ago

    FDA Supports De Novo Pathway for Dthera Sciences’ Breakthrough Alzheimer’s Device

    SAN DIEGO, CA / ACCESSWIRE / December 13, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, announced today that the U.S. Food and Drug Administration (FDA) has informed Dthera that it believes that a De Novo submission is the most appropriate regulatory pathway for DTHR-ALZ, as Dthera had proposed. DTHR-ALZ is a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. If granted clearance by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease.

  • ACCESSWIRE7 months ago

    Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase

    SAN DIEGO, CA / ACCESSWIRE / December 11, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, will be presenting at the Digital Medicine and MedTech Showcase 2019 on Tuesday, January 8 at 10:30am PST in San Francisco. Edward Cox, CEO of Dthera Sciences, will provide an update on the company's upcoming milestones and strategy. Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease.

  • ACCESSWIRE9 months ago

    Dthera Sciences Appoints Dr. Amir Kalali to Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / October 30, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce the appointment of Amir Kalali, M.D. to its Board of Directors. Dr. Kalali will also be Chairman of Dthera's Scientific Advisory Board. Dr. Kalali is recognized globally as a leading innovator at the intersection of life sciences and technology, advising companies on building the future of their business at the board level or as a strategic advisor.

  • ACCESSWIRE10 months ago

    Digital Therapeutic Leaders Dthera Sciences' and Click Therapeutics' Executives to act as Co-Chairs of Second Digital Therapeutics Summit

    SAN DIEGO, CA / ACCESSWIRE / September 25, 2018 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, is pleased to announce that its CEO, Edward Cox, has been ...

  • ACCESSWIRE10 months ago

    Dthera Sciences Announces Reverse Split

    SAN DIEGO, CA / ACCESSWIRE / September 25, 2018 / Dthera™ Sciences (DTHR) (DTHRD), the leading digital therapeutic company focusing on the elderly, announced today that the Company's stockholders approved an amendment to the Company's Articles of Incorporation to effectuate a reverse stock split of the Company's outstanding common stock. Effective September 25, 2018, a 1-for-20 reverse stock split of the Company's common stock will take effect, with shares trading on a post-split adjusted basis on September 25, 2018. "This reverse split is a key step in executing our long-term plan of achieving a National Exchange listing, such as the NASDAQ, in 2018," said Dthera CEO Edward Cox.

  • ACCESSWIRE11 months ago

    Dthera Sciences to Present at the 7th Annual Liolios Gateway Conference on September 5, 2018

    SAN DIEGO, CA / ACCESSWIRE / August 30, 2018 / Dthera™ Sciences (OTCQB: DTHR), the leading digital therapeutic company focusing on the elderly, has been invited to present at the 7th Annual Liolios Gateway ...

  • ACCESSWIRE11 months ago

    Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product ''DTHR-ALZ''

    SAN DIEGO, CA / ACCESSWIRE / August 23, 2018 / Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ. DTHR-ALZ, if granted approval, would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease. The proposed indication for use states that "DTHR-ALZ is intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer's type." To the Company's knowledge, Dthera Sciences is only the second digital therapeutics company to obtain Breakthrough Device designation from the FDA.

  • Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product "DTHR-ALZ"
    PR Newswire11 months ago

    Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer's Focused Development-Stage Product "DTHR-ALZ"

    SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Dthera™ Sciences (DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ. DTHR-ALZ, if granted approval, would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease. The proposed indication for use states that "DTHR-ALZ is intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer's type." To the Company's knowledge, Dthera Sciences is only the second digital therapeutics company to obtain Breakthrough Device designation from the FDA.

  • ACCESSWIRElast year

    Dthera Sciences Launches ReminX - The First Digital Therapeutic Consumer Health Product for Individuals with Alzheimer's Disease and Social Isolation

    SAN DIEGO, CA / ACCESSWIRE / August 1, 2018 / Dthera™ Sciences (DTHR), a San Diego-based digital therapeutics company developing innovative quality of life therapies for the elderly, announced the launch of ReminX™, an artificial-intelligence-powered consumer health product designed to digitally deliver Reminiscence Therapy to individuals suffering from Alzheimer's and other dementias, as well as from social isolation. According to the Alzheimer's Association, Alzheimer's disease is the only top 10 cause of death that cannot be prevented, cured, or slowed. Additionally, nearly half of elderly Americans are estimated to be impacted by social isolation, and AARP estimates the health effects of social isolation to be equivalent to smoking 15 cigarettes per day.

  • ACCESSWIRElast year

    Dthera Sciences Closes Private Placement Ahead of Commercial Launch

    SAN DIEGO, CA / ACCESSWIRE / July 23, 2018 / Dthera Sciences (DTHR), a digital therapeutics company developing innovative quality of life therapies for the elderly, has received the final tranche of investment into its previously announced pre-launch equity private placement. "We are pleased to have closed our Pre-Launch Financing Round ahead the upcoming launch of ReminX," said Edward Cox, CEO of Dthera Sciences. "The timing and terms of this financing provide strong affirmation by investors regarding the company's inherent value.